Overview: PDL1 Dako 22C3 TestIntroduction: The PDL1 Dako 22C3 Test tests for PDL1 expression using Dako 22C3 to guide immunotherapy for cancers like lung cancer, helping optimize treatment plans. Affecting 1 in 10 people with lung cancer, PDL1 expression poses diagnostic challenges due to tumor heterogeneity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses immunohistochemistry for high accuracy, supporting histopathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: PDL1 Dako 22C3 Expression Test, Immunotherapy Marker Assay.
FDA Status: FDA-approved test, meeting histopathology standards for diagnostic reliability.
Historical Milestone: PDL1 testing began in the 2010s with research by Topalian, who linked it to immunotherapy. Immunohistochemistry advancements by Dako improved detection, surpassing earlier manual methods.
Purpose: Detects PDL1 expression (Dako 22C3) to guide immunotherapy, optimizes treatment plans, and evaluates patients with cancer history, aiming to improve survival.
Test Parameters: PDL1 expression (Dako 22C3)
Pretest Condition: Tissue biopsy required. Collect tissue. Report history of cancer.
Specimen: Tissue (FFPE, 0.5-2 cma³); Tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or respiratory symptoms. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, treatment risks, and sample collection risks.
Procedural Considerations: Uses immunohistochemistry to detect expression, requiring labs with staining facilities. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: High expression suggests immunotherapy benefit, guiding therapy. Early treatment might improve outcomes, while untreated cases lead to progression. Normal levels may require other tests.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Biopsy, CT scan, or tumor mutational burden to confirm diagnosis.
Test Limitations: Specific to Dako 22C3; correlation with clinical status needed. False negatives possible with low expression.
References: NCCN Guidelines, 2023; New England Journal of Medicine, Topalian SL, 2022.
